Cadila Pharmaceuticals, one of the oldest and largest privately-held pharma companies in the country, has appointed Ashraf Allam as the Global Chief Operating Officer (COO) on November 30, 2022.

He will be based at the corporate office and will report to Cadila’s Group CMD Dr. Rajiv Modi.

Allam was serving recently as the CEO at Public Investment Fund prior to joining Cadila Pharmaceuticals.

He also serves as a board member for a number of US, European, and regional pharma, biotech, medical devices, diagnostics, self-medication and technology companies. In addition, he is also serving as senior executive advisor for global private equity funds and family offices both in the USA, Europe, and Middle East.

Ashraf has a strong track record of holding senior positions at global multinational and privately-held companies such as Johnson & Johnson, Amgen, Eli Lilly, BMS, and Mundipharma. He brings a great mix of leadership, inspiration, operational experience, technical breadth, and passion for patients.

“Cadila Pharmaceuticals is one of the oldest and most reputable well-established industry leaders both in India and globally. I look forward to working with Cadila’s executives and board of directors to drive a global powerhouse while upholding Cadila’s fundamental core principles; bringing both innovative and affordable medications to patients across the globe and always looking for innovative ways to transform the journey of patient care," said Allam.